These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38498141)

  • 1. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.
    Kristensen LE; Keiserman M; Papp K; McCasland L; White D; Carter K; Lippe R; Photowala H; Drogaris L; Soliman AM; Chen M; Padilla B; Behrens F
    Rheumatol Ther; 2024 Jun; 11(3):617-632. PubMed ID: 38498141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial.
    Östör A; Van den Bosch F; Papp K; Asnal C; Blanco R; Aelion J; Carter K; Stakias V; Lippe R; Drogaris L; Soliman AM; Chen MM; Padilla B; Kivitz A
    Rheumatol Ther; 2024 Jun; 11(3):633-648. PubMed ID: 38498139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study.
    Kristensen LE; Keiserman M; Papp K; McCasland L; White D; Lu W; Soliman AM; Eldred A; Barcomb L; Behrens F
    Rheumatology (Oxford); 2023 Jun; 62(6):2113-2121. PubMed ID: 36282530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.
    Kristensen LE; Keiserman M; Papp K; McCasland L; White D; Lu W; Wang Z; Soliman AM; Eldred A; Barcomb L; Behrens F
    Ann Rheum Dis; 2022 Feb; 81(2):225-231. PubMed ID: 34911706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study.
    Östör A; Van den Bosch F; Papp K; Asnal C; Blanco R; Aelion J; Lu W; Wang Z; Soliman AM; Eldred A; Padilla B; Kivitz A
    Rheumatology (Oxford); 2023 Jun; 62(6):2122-2129. PubMed ID: 36282537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.
    Östör A; Van den Bosch F; Papp K; Asnal C; Blanco R; Aelion J; Alperovich G; Lu W; Wang Z; Soliman AM; Eldred A; Barcomb L; Kivitz A
    Ann Rheum Dis; 2022 Mar; 81(3):351-358. PubMed ID: 34815219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials.
    Merola JF; Armstrong A; Khattri S; Paek SY; Padilla B; Yue C; Photowala H; Kaplan B; Kristensen LE
    J Dermatolog Treat; 2024 Dec; 35(1):2342383. PubMed ID: 38632977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial.
    Mease PJ; Kellner H; Morita A; Kivitz AJ; Aslanyan S; Padula SJ; Topp AS; Eldred A; Behrens F; Papp KA
    Rheumatol Ther; 2022 Oct; 9(5):1361-1375. PubMed ID: 35931879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1.
    Kristensen LE; Soliman AM; Papp K; White D; Barcomb L; Lu W; Eldred A; Behrens F
    Rheumatology (Oxford); 2023 Feb; 62(2):629-637. PubMed ID: 35801915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Mease PJ; Warren RB; Nash P; Grouin JM; Lyris N; Willems D; Taieb V; Eells J; McInnes IB
    Rheumatol Ther; 2024 Oct; 11(5):1403-1412. PubMed ID: 39120849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials.
    Kwatra SG; Khattri S; Amin AZ; Ranza R; Kaplan B; Shi L; Padilla B; Soliman AM; McGonagle D
    Dermatol Ther (Heidelb); 2024 Jun; 14(6):1517-1530. PubMed ID: 38739215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study.
    Ogdie A; Merola JF; Mease PJ; Ritchlin CT; Scher JU; Lafferty KP; Chan D; Chakravarty SD; Langholff W; Wang Y; Choi O; Krol Y; Gottlieb AB
    BMC Rheumatol; 2024 May; 8(1):20. PubMed ID: 38773563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
    Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
    JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.
    Rubbert-Roth A; Kato K; Haraoui B; Rischmueller M; Liu Y; Khan N; Camp HS; Xavier RM
    Rheumatol Ther; 2024 Oct; 11(5):1197-1215. PubMed ID: 39031276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics and Exposure-Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis.
    Thakre N; D'Cunha R; Goebel A; Liu W; Pang Y; Suleiman AA
    Rheumatol Ther; 2022 Dec; 9(6):1587-1603. PubMed ID: 36178584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
    Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
    J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Risankizumab in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Su QY; Zhou HN; Xia GM; Zhang RY; Tian HY; Su C; Liu YX; Zhang HY; Cheng T; Huo YH; Li Q; Zhang SX
    Rheumatol Ther; 2024 Apr; 11(2):227-237. PubMed ID: 38302785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study.
    Ritchlin CT; Mease PJ; Boehncke WH; Tesser J; Chakravarty SD; Rampakakis E; Shawi M; Schiopu E; Merola JF; McInnes IB; Deodhar A
    Clin Rheumatol; 2024 Aug; 43(8):2551-2563. PubMed ID: 38844682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.